We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

tDCS for the Treatment of Migraine

This study is currently recruiting participants.
Verified May 2016 by Kátia Monte-Silva, Universidade Federal de Pernambuco
Sponsor:
ClinicalTrials.gov Identifier:
NCT02562196
First Posted: September 29, 2015
Last Update Posted: May 11, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Kátia Monte-Silva, Universidade Federal de Pernambuco
  Purpose
The aim of this study is to evaluate an optimized protocol of tDCS that normalize the lack of habituation and efficiency of inhibitory cortical circuits in migraine patients. For this purpose, migraineurs volunteers will undergo to optimized tDCS protocol or sham tDCS.

Condition Intervention Phase
Migraine Disorders Device: tdcs Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Transcranial Direct Current Stimulation (tDCS) Optimized Protocol for the Treatment of Migraine

Resource links provided by NLM:


Further study details as provided by Kátia Monte-Silva, Universidade Federal de Pernambuco:

Primary Outcome Measures:
  • Change in headache diary variables [ Time Frame: 3 followed months ]
    it will be evaluated the number of migraine attacks, pain intensity, duration of each attack and number of painkillers intake. Patients will answer this diary during all experimental period (months).


Secondary Outcome Measures:
  • Changes on Visual Evoked Potentials measures [ Time Frame: at baseline, 1 month and 2 months, 3 months ]
    volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz. Electrodes used to record data will be localized on Oz and Fz points according International 10-20 system. During the test, 600 cortical answers will be recorded. Data will be collected and recorded in a personal computer, and after, converted to the ".txt" format to futures analysis with MATLAB.

  • Changes on HIT-6 [ Time Frame: at baseline, 1 month and 2 months, 3 months. ]
    this is a questionnaire, composed of six questions, developed to measure the impact of headache on daily living activities of individuals with chronic episodic and migraine. It is a valid and reliable instrument for this population and its results are related to clinic parameters of migraine, e.g. severity and quality of life. Total score ranges from 36 to 78 and it is categorized into four levels: slight or no impact (38 to 49 points); some impact (50 to 55 points); substantial impact (56-59 points); very severe impact (60 or more points). The minimum important difference for this scale was estimated at -2.5 to -5.5 points (within groups) and -1.5 points (between groups).

  • Changes on MIDAS [ Time Frame: at baseline, 1 month and 2 months, 3 months. ]
    this is a questionnaire, composed of five items, created to evaluate disability caused by headache in a period of 3 months. This instrument is reliable and validated in several countries, and its Portuguese version may be used to identify severe cases of migraine. MIDAS total score will be obtained by adding days lost in each of the areas being categorized into four levels: slight or none disability (0 to 5 days); mild disability (6 to 10 days); moderate disability (11 to 20 days); intense capacity (≥21 days).

  • Changes on VAS [ Time Frame: at baseline, 1 month and 2 months, 3 months. ]
    this scale will be used to measure the patients' pain intensity. VAS is an important instrument to verify, reliably, the patient's evolution during treatment. This scale will be used at beginning and end of each period (observation and treatment), before and after each tDCS session. For the VAS use, pain intensity will be asked to the patient. 0 cm means total pain absence and 10 cm is the level of maximum pain bearable by the patient.

  • Changes on motor evoked potentials [ Time Frame: through study completion, assessed up to 1 month (before and after each section) ]
    to measure MEP, the intensity of the magnetic stimulator will be adjusted to 120% of rest motor threshold and 10 stimuli will be registered. For evaluation volunteers will be instructed to sit in a chair and get into a comfortable position. Initially, single-pulse transcranial magnetic stimulation (TMS) will be administered over the motor cortex to determine the cortical representation area of the first dorsal interosseous muscle (FDI). For all evaluations the same figure-eight coil is used, in order to avoid measurement bias. Amplitude means of evoked potentials will determine the MEP.

  • Changes on inhibition and facilitation [ Time Frame: through study completion, assessed up to 1 month (before and after each section) ]
    to evaluate these variables, subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at an inter stimulus intervals (ISI) of 2 milliseconds, to determine the short interval cortical inhibition (SICI). The Intracortical facilitation (ICF) will be evaluated by the MEP average at an ISI of 10 milliseconds. Ten stimulus will be applied in each condition (unconditioned pulse, and pairs of stimuli with ISI of 2 and 10 milliseconds). The order of stimulus delivered will be pseudorandomized and SICI and ICF will be expressed as a percentage of a conditioned stimuli in regarding an unconditioned stimuli.

  • Changes from phosphene threshold [ Time Frame: through study completion, assessed up to 1 month (before and after each section) ]
    a 10-cm circular coil was used that has giving a peak magnetic field strength of 2 tesla. Subjects were asked to wear a blindfold, sit comfortably in a chair and to close their eyes to diminish ambient light.In sagittal line, three points were scored: 2, 3 and 4 cm above the inion. The single pulse TMS was applied to one of the points scored and the subject was asked to report the presence or absence of a phosphene immediately after stimulation. The stimulation was repeated ten times at each intensity with a maximum frequency of 0.2 Hz, stimulation was initially applied to 60% of the maximum intensity of the stimulator. The intensity of stimulation was changed into blocks of 5% to minimum intensity that the subject can perceive the phosphene certainly, five times ten, then this value was set as the PT.


Estimated Enrollment: 14
Study Start Date: March 2016
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: optimized protocol chosen
a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
Device: tdcs

The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.

To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.

Sham Comparator: sham tDCS
a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
Device: tdcs

The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.

To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.


Detailed Description:
A randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. Electrical cortical activity will be assessed through: (i) motor evoked potential (MEP); (ii) motor threshold (MT); (iii) short interval intracortical inhibition (SICI); (iv) intracortical facilitation (ICF); (v) phosphene threshold (PT) and (vi) visual evoked-potential (VEP-habituation). Clinical outcomes will be evaluated through: (i) headache diary; (ii) visual analog scale (VAS); (iii) Migrainde disability assessment (MIDAS); (iv) Headache Impact Test (HIT-6) and (v) World Health Organization quality of life assessment instrument (WHOQOL BREF).
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presented diagnostic of episodic migraine with or without aura or probably migraine with or without aura according to the criteria for diagnosis of International Classification of Headache Disorders (ICHD-III)
  • Disease duration of at least 12 months
  • Without preventive medication for at least 6 months prior to initiation of treatment

Exclusion Criteria:

  • Pregnant women;
  • Pacemaker;
  • History of seizures;
  • Metallic implants in the head;
  • Patients with clinical evidence of brain injuries;
  • Chronic pain associated to others diseases;
  • Use of neuroleptic medications
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02562196


Contacts
Contact: Kátia Monte-Silva, PhD monte.silvakk@gmail.com
Contact: Sérgio Rocha, MsC srocha3105@gmail.com

Locations
Brazil
Applied Neuroscience Laboratory Recruiting
Recife, Pernambuco, Brazil
Contact: Sergio Rocha       srocha3105@gmail.com   
Sponsors and Collaborators
Universidade Federal de Pernambuco
Investigators
Principal Investigator: Kátia Monte-Silva, PhD Universidade Federal de Pernambuco
  More Information

Responsible Party: Kátia Monte-Silva, Effect of Transcranial Direct Current Stimulation (tDCS) Optimized Protocol for the Treatment of Migraine, Universidade Federal de Pernambuco
ClinicalTrials.gov Identifier: NCT02562196     History of Changes
Other Study ID Numbers: Effect_tDCS_Migraine
First Submitted: September 22, 2015
First Posted: September 29, 2015
Last Update Posted: May 11, 2016
Last Verified: May 2016

Keywords provided by Kátia Monte-Silva, Universidade Federal de Pernambuco:
migraine disorders
transcranial direct current stimulation
electric stimulation therapy
pain

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases